Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | dna polymerase kappa | 0.0023 | 0.3387 | 0.5 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.3387 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.3387 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 1 | 1 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.3387 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 1 | 0.5 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 0.3387 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 1 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.3387 | 0.5 |
Echinococcus granulosus | dna polymerase kappa | 0.0023 | 0.3387 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 1 | 1 |
Schistosoma mansoni | DNA polymerase eta | 0.0023 | 0.3387 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.3387 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 1 | 0.5 |
Echinococcus multilocularis | dna polymerase eta | 0.0023 | 0.3387 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.3387 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.3387 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 1 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0023 | 0.3387 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 1 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.3387 | 0.3387 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 1 | 1 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.3387 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.3387 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.3387 | 0.5 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 0.3387 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.3387 | 0.3387 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.1 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.5481 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 37.6505 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.